IPP Bureau
Lupin secures global Great Place To Work certification for 2026-27
By IPP Bureau - April 07, 2026
Recognition across subsidiaries and geographies highlights pharma major’s focus on inclusive culture, employee experience, and global workforce development
Alembic Pharma wins USFDA nod for generic Dapagliflozin, secures 180-day exclusivity
By IPP Bureau - April 07, 2026
Final approval for diabetes and heart-failure drug opens access to a $10.5 billion US market opportunity, with shared exclusivity benefits.
Thyrocare’s Bharat Aarogyam score flags silent health risks in 9 out of 10 Indians
By IPP Bureau - April 07, 2026
Analysis of over 93 lakh preventive health checkups reveals disease risks emerging as early as the 20s
Apollo report warns India’s silent health risks are striking earlier among young adults
By IPP Bureau - April 07, 2026
Health of the Nation 2026, based on over 3 million assessments, finds rising diabetes, obesity, and hidden cardiac risks in under-30s and working professionals
Practo reports surge in lifestyle disease awareness within Tier 2 cities, led by metabolic health searches
By IPP Bureau - April 07, 2026
Searches for diabetes, heart conditions, and metabolism-related risks are rising sharply, with Tier 2 cities outpacing metros in specialist consultations
AstraZeneca India, Telangana Govt partner for AI-led lung cancer screening in public hospitals
By IPP Bureau - April 07, 2026
MoU to deploy Qure.ai’s chest X-ray solution across 20 government facilities aims to improve early detection in urban and rural populations
Vedanta’s community healthcare programmes reach 30 lakh people, FY26 spend crosses Rs 50 crore
By IPP Bureau - April 07, 2026
The last-mile healthcare delivery across 1,100 villages, with focus on maternal health, diagnostics, and chronic disease management
SIMPACT 2026 convenes India’s healthcare leaders to advance simulation-driven education
By IPP Bureau - April 06, 2026
Participants also experienced a VR-enabled learning environment designed to support clinical skill development in controlled, repeatable, and risk-free settings
Dharmendra Singh Gangwar appointed CEO of Rajiv Gandhi Cancer Institute
By IPP Bureau - April 06, 2026
Former Interim CEO takes charge to drive strategic growth, strengthen clinical excellence, and advance patient-centric oncology innovation
Syngene appoints Maninder Kapoor Puri as Chief Human Resources Officer
By IPP Bureau - April 06, 2026
Veteran HR leader comes with over two decades of experience to spearhead talent strategy, leadership development, and culture transformation
Sir Ganga Ram Hospital launches dialysis center in Gurgaon to expand renal care access
By IPP Bureau - April 06, 2026
New facility in Sector 51 offers advanced, affordable, and patient-centric dialysis services for NCR patients
Red Nucleus acquires Bridge Medical Consulting with advisory support from VERTICES PARTNERS
By IPP Bureau - April 06, 2026
As part of the deal, Red Nucleus also gains indirect ownership of the company’s Indian arm
Samsung Biologics lands first US manufacturing facility with GSK acquisition
By IPP Bureau - April 06, 2026
Samsung Biologics will continue supplying products previously manufactured at the site to GSK
AstraZeneca, Roche-backed study supports risk-based HF screening in diabetes
By IPP Bureau - April 06, 2026
Researchers say simple blood-test and echocardiography pathway could reshape diabetes-related cardiovascular care
Enveric Biosciences bags key US patent for mental health drug
By IPP Bureau - April 06, 2026
EB-003 is Enveric’s lead neuroplastogen, a 5-HT2A / 5-HT1B dual-acting compound designed to promote neuroplastic changes
